Merck & Company Inc (MRK)vsRadNet Inc (RDNT)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
RDNT
RadNet Inc
$54.34
+2.90%
HEALTHCARE · Cap: $4.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2967% more annual revenue ($65.77B vs $2.14B). MRK leads profitability with a 13.6% profit margin vs -0.7%. RDNT appears more attractively valued with a PEG of 0.96. RDNT earns a higher WallStSmart Score of 54/100 (C-).
MRK
Hold50
out of 100
Grade: D+
RDNT
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for RDNT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 75.0% YoY
Growing faster than its price suggests
Revenue surging 22.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Elevated debt levels
Weak financial health signals
ROE of -1.3% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RDNT
The strongest argument for RDNT centers on EPS Growth, PEG Ratio, Revenue Growth. Revenue growth of 22.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RDNT
The primary concerns for RDNT are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.79 is elevated, increasing financial risk.
Key Dynamics to Monitor
MRK profiles as a value stock while RDNT is a growth play — different risk/reward profiles.
RDNT carries more volatility with a beta of 1.39 — expect wider price swings.
RDNT is growing revenue faster at 22.1% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
RDNT scores higher overall (54/100 vs 50/100) and 22.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →RadNet Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?